Alembic launches generic Tamiflu
Alembic Pharmaceuticals is introducing its generic Tamiflu (oseltamivir phosphate capsules. The generic is indicated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for less than 48 hours.
Alembic’s generic will be available in three dosage strengths — 30 mg, 45 mg and 75 mg — in 1x10 unit dose blister packs.
The company noted that this markets its 53nd product launch since it commenced U.S. operations in October 2015.